Affymetrix (AFFX) is the Chart of the Day. The molecular biology technology company has had ups and downs but is still up over 63% year to date.
Article:
The Chart of the Day is Affymetrix (AFFX). I found the stock by sorting the New High List for frequency and this stock was near the top. The stock hit 18 new highs and gained 44.17% in the last month and continues to climb.
The company's scientists invented the world's first high-density microarray and began selling the first commercial microarray. Since then, their GeneChip technology has become the industry standard in molecular biology research. The firm's technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. Their patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health.
Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.
Barchart technical indicators:
- 88% Barchart technical buy signals
- Trend Spotter buy signal
- Above its 20, 50 and 100 day moving averages
- 18 new highs and up 44.17% in the last month
- Relative Strength Index 80.51%
- Barchart computes a technical support level at 4.41
- Recently traded at 5.91 with a 50 day moving average of 3.90
Fundamental factors:
- Market Cap $368.75 million
- Revenue projected to grow 7.80% this year and 2.20% next year
- Earnings estimated to increase by 100.00% this year and continue to increase by 33.00% annually for the next 5 years
- Wall Street analysis issued 1 strong buy, 2 buy, 7 hold and 3 under perform recommendations for their clients
- Financial Strength C+
This stock has gone up and down over the year as analysts and investors changed their minds. Watch the momentum closely and don't stay too long.
No comments:
Post a Comment